October 18, 2024 10:29 AM EDTUpdated 03:21 PM
R&D
Pharma

Pfiz­er ends tri­al of Ar­ray-ac­quired SHP2 in­hibitor af­ter sim­i­lar cuts from peers

Kyle LaHucik

Senior Reporter

Pfiz­er has end­ed its tri­al of an SHP2 in­hibitor that was be­ing de­vel­oped in can­cer, the lat­est blow to the tar­get af­ter sev­er­al oth­er drug­mak­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times